CDK4 and cancer: There are mutations or over-activation of CDK4/6 in a variety of cancer tissues (Otto and Sicinski, 2017), so CDK4/6 has always been regarded as an important target for drug development (Niesvizky et al., 2015; Tadesse et al., 2015).